Menu
Search Close

News

Scancell to present at the 23rd Annual NewsMakers in the Biotech Industry Conference in NYC

07th September 2016

Scancell Holdings plc, (‘Scancell’ or the ‘Company’) the developer of novel immunotherapies for the treatment of cancer, announces that it will be presenting at the 23rd Annual NewsMakers in the Biotech Industry Conference. The conference is being held on 9 September 2016 at the Millennium Broadway Hotel & Conference Center in New York City, USA.

Dr John Chiplin, Executive Chairman of Scancell, will be presenting an overview of the Company at 15:00 ET in presentation room 311 and will be available to participate in one-on-one meetings with investors who
are registered to attend the conference.

For Further Information:

Dr John Chiplin, Executive Chairman

Dr Richard Goodfellow, CEO

Scancell Holdings Plc

+1 858 900 2646

+44 (0) 20 3727 1000

Freddy Crossley (Corporate Finance)

Tom Salvesen (Corporate Broking)

Panmure Gordon & Co

+44 (0) 20 7886 2500

+44 (0) 20 7886 2500

Mo Noonan/Simon Conway

FTI Consulting

+44 (0) 20 3727 1000



About NewsMakers in the Biotech Industry Conference

NewsMakers presents a hand-picked group of public biotech companies whose corporate and regulatory milestones will drive stock prices. NewsMakers is recognized as the industry's key venue for companies to
take their story to Wall Street each Fall. Thus, NewsMakers remains the best opportunity for business development executives and key members of the institutional investment and analyst communities to compare notes and assess the industry landscape.

Last year, more than 500 delegates congregated at NewsMakers, including money managers who controlled more than $480 billion in equity assets, with over $50 billion dedicated to healthcare and $15 billion
dedicated to biotech.

About Scancell

Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms.
Scancell’s first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma. Data from the Phase 1/2 clinical trial demonstrate that SCIB1, when used as monotherapy, has a marked effect on tumour
load, produces a melanoma-specific immune response and highly encouraging survival trend without serious side effects. In patients with resected disease there is increasing evidence to suggest that SCIB1 may delay or prevent disease recurrence.

Scancell’s ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system: the helper cell system where inflammation is stimulated at the tumour site and the cytotoxic Tlymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.

Pre-clinical data on a combination of SCIB1 or SCIB2 and checkpoint inhibition (blockade of the PD-1 or CTLA-4 immune checkpoint pathways) have shown enhanced tumour destruction and significantly longer
survival times than when either treatment was used alone.
Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4+ T cells that destroy tumours without toxicity. The Directors believe that the Moditope® platform could
play a major role in the development of safe and effective cancer immunotherapies in the future.

Webcasts, Interviews and Media Coverage

Scancell raises £5mln in 'most successful round they've ever had' - CEO Richard Goodfellow

Richard Goodfellow, chief executive of Scancell Holdings Plc (LON:SCLP) talks through with Proactive Investors their £5mln raise to fund clinical work on their pipeline of cancer immune-therapies.

Fri, 12 May 2017 07:57:00

Scancell Holdings raises £5mln as pace of clinical work quickens

The money will support clinical work on its pipeline of cancer immunotherapies and in particular Modi-1, the first product from its Moditope platform.

Thu, 11 May 2017 12:00:00

Scancell boss 'very excited' about collaboration deal with leading US lung cancer foundation

Scancell Holdings Plc (LON:SCLP) has confirmed it will kick off a phase II clinical trial of its potentially breakthrough cancer treatment in the second half.

CEO Richard Goodfellow also tells Proactive's Andrew Scott they've found a partner to help them with a phase I/II clinical study of SCIB2 for patients with lung cancer.

Wed, 01 Feb 2017 09:53:00